This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In effect, the revisions to the FD&C Act and the PHS Act are designed to encourage the use of alternatives to animaltesting not eliminate animaltesting in drug development. adequate to justify the proposed clinical testing.” The pre-existing statutory language did not require animaltesting.
The Court maintained that, to annul this non-renewal on the basis of a lack of transparency, the firms would have to identify “an express provision conferring on [them] a procedural right” within the relevant governing framework legislation to be informed of these developments.
European Commission issues EU-wide rules on pesticide ingredients The Commission has issued uniform rules governing data requirements and a work program for safeners and synergists, constituent compounds that, like active substances, must be approved for use in plant protection products in the EU.
At conference, ECHA calls for regulatory coherence, collaboration to achieve green and digital transition Last week, EU chemicals regulator ECHA brought together experts from industry, government, civil society, research, and academia to discuss the future of EU chemicals regulation.
Animaltesting plays a significant role in pre-clinical research and therefore requires the use of millions of animals. million scientific procedures involving live animals were carried out in 2020. million scientific procedures involving live animals were carried out in 2020. In Britain, 2.88 In Britain, 2.88
varies based on government agency. E Evidence of Non-carcinogenicity for Humans Agents that show no evidence for carcinogenicity in at least two adequate animaltests in different species or in both adequate epidemiologic and animal studies.
It may seem that if researchers are sufficiently concerned about the welfare of lab animals, the best thing to do would be to stop using animals altogether. However, a multitude of factors—from institutional inertia to a global animal-testing industry worth billions of dollars —make this outcome unlikely.
The bills have been in legislative purgatory for months as Congressional infighting has prevented the passage of a FY2024 appropriations bill to fund the government. The new bill is intended to serve as the FY2024 appropriations, and stave off a shutdown of government operations.
Mendel first published his findings on the principles governing the inheritance of traits for color and shape in peas in 1866, but his findings languished in obscurity until 1900. Before Mendel, the prevailing theory was that offspring inherited the blended , or “averaged” traits of their parents.
Rademacher explained that their approach bypasses the need for traditional animaltesting: Everybody asks us why we don’t test our vaccines in monkeys and rabbits. The strength of the data convinced the Brazilian government to license Gyldens dengue vaccine for all of Brazil and Latin America.
This proposed rule, if finalized, would implement the pediatric study plans provisions of the FD&C Act, and exercise the authority granted to the Secretary in the provisions of the FD&C Act governing exemptions from pediatric study requirements. It’s also interesting to see what isn’t on this list.
Although it is a setback for one of the most promising treatment approaches for COVID-19, Lilly said in a statement that the government is continuing a separate study testing the antibody drug in mild to moderately ill patients, to try to prevent hospitalization and severe illness. In Texas, Gov.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content